发明名称 Quinoxalines and AZA-quinoxalines as CRTH<sub>2 </sub>receptor modulators
摘要 The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J1, J2, R1, R2, R3, R22, Ra, Rb, Rc, Rd, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.;
申请公布号 US9469615(B2) 申请公布日期 2016.10.18
申请号 US201113996361 申请日期 2011.12.19
申请人 Merck Sharp & Dohme Corp. 发明人 Boyce Christopher W.;Degrado Sylvia Joanna;Chen Xiao;Qin Jun;Mazzola, Jr. Robert D.;Yu Younong;McCormick Kevin D.;Palani Anandan;Xiao Dong;Aslanian Robert George;Wu Jie;Rao Ashwin Umesh;Siliphaivanh Phieng;Methot Joey L.;Zhang Hongjun;Kelley Elizabeth Helen;Brown William Colby;Jiang Qin;Gauuan Jolicia Polivina;Leyhane Andrew J.;Biju Purakkattle Johny;Dhondi Pawan K.;Dong Li;Fevrier Salem;Huang Xianhai;Vaccaro Henry M.
分类号 C07D241/38;C07D241/42;A61K31/498;A61K31/506;A61K31/4985;A61K31/55;A61K45/06;C07D401/12;C07D401/14;C07D405/12;C07D409/12;C07D413/12;C07D413/14;C07D417/12;C07D451/02;C07D471/08;C07D487/04;C07D487/08;C07D403/06;C07D471/04;C07D471/10;C07D491/107;C07D498/04;C07D403/12;C07D401/06;C07D403/14;C07D409/14;C07D413/06;C07D241/44;C07D417/14;C07D491/048;C07D498/10 主分类号 C07D241/38
代理机构 代理人 Meade Eric A.;Cocuzzo Anna L.
主权项 1. A compound of the formula (I) or a pharmaceutically acceptable salt thereof, wherein J1 and J2 are independently C(H), C(R1), C(R22), or N wherein the following provisos apply (i) no more than one of J1 and J2 is N,(ii) no more than one of J1 and J2 is C(R22); and(iii) only one R1 is substituted on the illustrated ring containing J1 and J2; R1 is selected from the group consisting of (i) —C(O)—N(R6a)(R6b),(ii) —S(O)2—N(R6a)(R6b),(iii) —C(O)—C(R7a)(R7b)(R7c),(iv) —N(H)—C(O)—C(R7a)(R7b)(R7c),(v) —C(O)—O—C(R7a)(R7b)(Rc), and(vi) —N(H)—S(O)2—C(R7a)(R7b)(R7c); R6a and R6b are independently a. H,b. C1-C6 alkyl,c. C3-C6 alkenyl,d. C3-C6 alkynyl,e. —O—(C1-C3 alkyl),f. -Q-RAH, wherein RAH is phenyl or 5- to 6-membered heteroaryl containing 1 to 2 heteroatoms independently selected from the group consisting of N, O, and S, and wherein RAH is unsubstituted or substituted with 1 to 5 R8 moieties independently selected from the group consisting of halo, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 fluoroalkyl, —O—(C1-C3 fluoroalkyl), hydroxyl, phenyl, and —CN;Q is selected from the group consisting of (a) a bond;(b) C1-C6 alkylene, wherein said C1-C6 alkylene is unsubstituted or substituted by 1 to 2 fluoro, C1-C3 alkyl, C1-C3 hydroxyalkyl, or C1-C3 fluoroalkyl; and(c)  wherein t is 1, 2, 3, or 4;g. -Q-RHc, wherein RHC is (i) 5- to 7-membered heterocyclyl containing 1 heteroatom selected from the group consisting of N, O, S, S(O), and S(O)2, wherein said heterocyclyl of RHC is optionally fused to a benzene, pyridyl ring; or(ii) C3-C7 cycloalkyl, wherein said cycloalkyl of RHC is optionally fused to a benzene or pyridyl ring;and wherein RHC is unsubstituted or substituted with 1 to 5 R12 moieties independently selected from the group consisting of halo, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 fluoroalkyl, —O—(C1-C3 fluoroalkyl), hydroxyl, —CN, and —S(O)2—(C1-C3 alkyl), or wherein when two R12 moieties are geminally substituted on the same carbon atom, the two geminally substituted R12 moieties, together with the carbon atom on which they are attached form —C(O)—;Q is selected from the group consisting of (a) a bond;(b) C1-C6 alkylene, wherein said C1-C6 alkylene is unsubstituted or substituted by 1 to 2 fluoro, C1-C3 alkyl, C1-C3 hydroxyalkyl, or C1-C3 fluoroalkyl; and  wherein t is 1, 2, 3, or 4;h. or R6a and R6b together with the N atom to which they are attached form R6H, wherein R6H is independently selected from the group consisting of (i) a 4- to 9-membered heterocyclyl, optionally containing one additional nitrogen atom, wherein said heterocyclyl of R6H is optionally fused to phenyl, C3-C6 cycloalkyl, or a 5-membered heteroaryl containing 1 to 3 N atoms;(ii) a 4- to 7-membered heterocyclenyl, optionally containing one additional nitrogen atom, wherein said heterocyclenyl of R6H is optionally fused to phenyl; and(iii) a 6- to 8-membered aza- or a diazabicycloheterocycloalkyl ring;wherein R6H is unsubstituted or substituted by 1 to 5 R9 moieties wherein each R9 moiety is independently C1-C6 alkyl, C1-C6 alkoxy, C1-C3 fluoroalkyl, fluoro, hydroxyl, —CN, —(C1-C3 alkylene)-(C1-C3 alkoxy), orR9 is —Z—RCY wherein Z is (i) a bond, (ii) —C(O)—,(iii) —C(═N—OH)—, (iv) —S(O)2—, (v) C1-C3 alkylene, wherein said C1-C3 alkylene of Z is optionally substituted by 1 to 2 fluoro or C1-C3 alkyl; (vi) —O—; (vii) —O—(C1-C3 alkylene)-; or (viii) —C(O)—O—CH2— RCY is selected from the group consisting of (i) phenyl (ii) 5- to 10-membered mono or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S; or (iii) 5- to 6-membered heterocyclyl containing 1 to 2 N atoms or 1 O atom, wherein said heterocyclyl of RCY is optionally fused to phenyl; wherein RCY is unsubstituted or substituted by 1 to 4 RH) moieties; each R10 moiety is independently C1-C3 alkyl, halo, hydroxyl, C1-C3 alkoxy, C1-C3 fluoroalkyl, —(C1-C3 alkylene)-(C1-C3 alkoxy), —S(O)2—(C1-C3 alkyl), —C(O)—(C1-C3 alkyl), —CN, pyridyl, or cyclopropyl or, wherein when two R10 moieties are geminally substituted on a common carbon atom, together with the carbon atom on which they are substituted, form —C(O)—;or, optionally, where two R9 moieties are geminally substituted on a common ring carbon of R6H, the two R9 moieties, together with the ring carbon on which they are substituted, form RYC, wherein RYC is (i) a 4- to 7-membered cycloalkyl, wherein said cycloalkyl of RYC is optionally fused to phenyl or pyridyl; or (ii) a 4- to 7-membered heterocyclyl containing 1 to 2 N atoms or 1 O atom, wherein said heterocyclyl of RYC is optionally fused to phenyl; wherein RYC is unsubstituted or substituted by 1 to 4 R11 moieties; each R11 moiety is independently C1-C3 alkyl, halo, hydroxyl, C1-C3 alkoxy, —(C1-C3 alkylene)-(C1-C3 alkoxy), —S(O)2—(C1-C3 alkyl), —C(O)—(C1-C3 alkyl), phenyl, or pyridyl, or, wherein when two R11 moieties are geminally substituted on a common carbon atom, together with the carbon atom on which they are substituted, form —C(O)—;R7a and R7b are independently a) H,b) C1-C6 alkyl,c) R7a and R7b together with the carbon atom on which they are substituted, form RPC, wherein RPC is (i) C3-C7 cycloalkyl, or(ii) phenyl, wherein said phenyl of RPC is unsubstituted or substituted by 1 to 5 moieties independently selected from the group consisting of halo, trifluoromethyl, and trifluoromethoxy;R7c is a) H, orb) absent, when R7a and R7b together with the carbon atom on which they are substituted form phenyl; R22 is halo, C1-C3 alkyl, or C1-C3 fluoroalkyl; b is 0 or 1; X is a bond, —O—, —S—, —S(O)—, —S(O)2—, or N(H); Y is selected from the group consisting of (i) a bond,  (iv) —O—, (v) —S—, (vi) —S(O)—, and(vii) —S(O)2—; whereina is 0, 1, 2, or 3;r is 0, 1, or 2;s is 0, 1, or 2;each occurrence of R4 is independently halo, C1-C6 alkyl, or C1-C6 fluoroalkyl; Ra, Rb, Rc, and Rd are independently H, fluoro, hydroxyl, C1-C6 alkyl, C1-C6 fluoroalkyl, or C1-C6 alkoxy; R2 is selected from the group consisting of (i) phenyl; and(ii) 5- to 6-membered heteroaryl containing from 1 to 3 heteroatoms selected from the group consisting of N, O, and S;wherein R2 is unsubstituted or substituted by 1 to 5 R5 groups independently selected from the group consisting of halo, C1-C3 fluoroalkyl, C1-C3 alkyl, C1-C3 alkoxy, —CN, —OCF3, —C(O)—(C1-C3 alkyl), and —S(O)2—(C1-C3 alkyl); R3 is —C(O)OH,  or —N(H)—SO2—Re, wherein Re is C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 alkoxy, and phenyl; n is 1, 2, 3, 4, or 5; and q is 0, 1, or 2.
地址 Rahway NJ US